Use for detection of CBFB-MYH11 in acute myeloid leukemia (AML).
Reverse Transcription Polymerase Chain Reaction
This test is New York DOH approved.
- Patient Preparation
- Lavender (EDTA) or bone marrow (EDTA).
- Specimen Preparation
- Transport 5 mL whole blood or 3 mL bone marrow. (Min: 1 mL whole blood or 1 mL bone marrow) Specimens must be received within 48 hours of collection due to lability of RNA.
- Storage/Transport Temperature
- Unacceptable Conditions
- Serum or plasma. Frozen or clotted specimens. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed specimens.
- Ambient: 1 hour; Refrigerated: 48 hours; Frozen: Unacceptable
Refer to report.
See Compliance Statement B: www.aruplab.com/CS
CBFB (core binding factor β-chain)-MYH11 (myosin heavy chain 11 gene) fusion transcripts are detected in approximately 10% of de novo acute myelogenous leukemias (AML). One half of these cases belong to AML subtype M4 with abnormal eosinophils (AML-M4Eo). The fusion results from a pericentric inversion on chromosome 16 inv(16)(p13q22) or rarely from the translocation t(16;16)(p13;q22). Based on the breakpoints in the CBFB and MYH11 genes, greater than 95% of analyzed inv(16) cases belong to three types: A (88%), D (5%), and E (5%).
|Component Test Code*||Component Chart Name|
|0096364||CBFB-MYH11, inv(16) by RT-PCR|
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
- CBFB-MYH11 inv(16) fusion gene
- CBFB-MYH11 Inversion